Latest Breaking News On - Public health vaccines - Page 8 : vimarsana.com

Public Health Vaccines Announces the Initiation of the First Clinical Trial Evaluating Its Nipah Virus Vaccine

/PRNewswire/ Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA developing novel products against emerging infectious diseases,.

United statesUnited kingdomHeinz feldmannCrozet biopharmaThomas monath crozet biopharmaJoan fuscoLaboratory of drDivision of intramural researchCore teamBiomedical advanced researchNational institute of allergyNational institutes of healthDevelopment authorityPrnewswire public health vaccinesPublic health vaccinesLaboratory of virology

Nipah virus vaccine candidate Phase 1 clinical trial begins

Nipah virus vaccine candidate Phase 1 clinical trial begins
outbreaknewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outbreaknewstoday.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesHeinz feldmannCrozet biopharmaThomas monath crozet biopharmaJoan fuscoLaboratory of drDivision of intramural researchNational institute of allergyNational institutes of healthPublic health vaccinesLaboratory of virologyCoalition for epidemic preparednessIntramural researchNational instituteInfectious diseases

Additional $12mn to fund further development of Marburg virus vaccine

Additional $12mn to fund further development of Marburg virus vaccine
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Us biomedical advanced researchPublic health vaccinesDevelopment authorityCoalition for epidemic preparedness innovationsPublic health agencyCrozet biopharmaLatham biopharm group incUs department of homeland securityAdvanced researchEpidemic preparedness innovationsபொது ஆரோக்கியம் தடுப்பு மருந்துகள்வளர்ச்சி அதிகாரம்கூட்டணி க்கு பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் புதுமைகள்எங்களுக்கு துறை ஆஃப் தாயகம் பாதுகாப்புபெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் புதுமைகள்

Public Health Vaccines Awarded First Options Under Advanced Development Contract From BARDA to Continue Development of Vaccine Against Marburg Virus

Public Health Vaccines Awarded First Options Under Advanced Development Contract From BARDA to Continue Development of Vaccine Against Marburg Virus
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMichael mcginnisBiomedical advanced researchUs department of healthHuman servicesDevelopment authorityPublic health vaccinesCoalition for epidemic preparedness innovationsCrozet biopharmaPublic health agency of canadaOffice of theUs department of homeland securityLatham biopharm group incPublic health agencyAssistant secretary

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

Published: Jan 11, 2021 CAMBRIDGE, Mass. (BUSINESS WIRE) Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date. This announcement reflects the Company’s commitment to accelerating its infectious disease portfolio based on Moderna’s experience with its COVID-19 vaccine. The development programs announced today are mRNA vaccine candidates against seasonal flu, HIV and the Nipah virus. Moderna also announced an expansion of its respiratory syncytial virus (RSV) vaccine program into older adults.

United statesUnited kingdomIntratumoral immunoCorinne le goffLe goffRuchira glaserHead of clinical sciences for theMelinda gates foundationModerna new infectious disease vaccine development programsEuropean unionVaccine research centerUs department of healthNational institutes of healthHuman servicesDrug administrationDevelopment authority